Coinbase Founder’s Longevity Startup Triples in Value

by | Jun 2, 2026 | news, Top News

Spread the love
Now worth $3.1 billion, NewLimit plans to test its RNA therapy in alcohol-related liver-disease patients next year.

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments